Clinical Trial Update: Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) [Phase 1]

View source ↗

Summary

Sana Biotechnology's investigational candidate SC291 is being studied in a Phase 1 ARDENT trial for relapsed/refractory B-cell malignancies, including Non-Hodgk…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• SC291

Snippet

Sponsor: Sana Biotechnology | Conditions: Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Status: ACTIVE_NOT_RECRUITING